High Flow Oxygen Therapy Versus Conventional Oxygen Therapy in Cardiac Surgery Patients
Study Details
Study Description
Brief Summary
High flow oxygen therapy has been applied after extubation in cardiac surgery patients with uncertain efficacy. The current authors plan to conduct a prospective, randomized, controlled study of nasal high flow therapy (NHF) application with high (60L/min) or low flow (40L/min) oxygen mixture administration versus standard oxygen treatment (Venturi mask) after extubation of patients undergoing elective or non-elective cardiac surgery.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Over the past decade, nasal high flow (NHF) has been introduced for oxygen therapy in adults. Its indications have been expanded, especially in cases of acute hypoxemic respiratory failure.
The device consists of an air/oxygen blender connected via an active heated humidifier to a nasal cannula, through a single limb, heated inspiratory circuit. It delivers a fraction of inspired oxygen (FiO2) from 21% to 100% with a flow rate up to 60 L/min. FiO2 adjustments are independent of the set flow rate so that the patient is given heated, humidified high-flow oxygen, with a flow that can be adjusted above the patient's maximum inspiratory flow rate, thereby increasing confidence about the actual FiO2 being delivered to the patient. These device characteristics make it more promising in comparison with conventional low- and high-flow oxygen devices (e.g., nasal cannula, non-rebreathing masks, Venturi masks), especially in patients with high inspiratory flow rates, such as patients with acute respiratory failure (ARF).
The benefits arising from application of oxygen with high flow rates via NHF are
-
reduction in the entrainment of room air and thus ensuring higher and more stable FiO2 values,
-
generation of positive airway pressures during expiration as a result of the expiratory resistance imposed to the patient's exhalation against the continuous high flow of incoming oxygen gas,
-
improving mucociliary function and clearance of secretion by continuous heating and humidifying of the administered gas,
-
reducing dead space ventilation and
-
reducing work of breathing. All the aforementioned NHF mechanisms of actions exert various effects on the respiratory system, including improved gas exchange, lower respiratory rate and effort and improved lung mechanics which are correlated with more comfort and less subjective dyspnea.
Respiratory complications after cardiac surgery can affect morbidity and mortality, and increase the healthcare cost. Advanced age, duration of extracorporeal circulation, history of significant underlying cardiac or pulmonary disease and phrenic nerve injury are the main prognostic factors for post cardiac surgery respiratory complications.
Traditionally, low- and high-flow oxygen systems are used to reverse postsurgical respiratory complications with or without addition of continuous (CPAP) or bi-level (NIV) positive airway pressure.
NHF might be superior for the prevention or treatment of those respiratory complications, since it can provide high-flow of heated and hydrated oxygen while the positive airway pressure created by the high gas flow can recruit alveoli and increase the end-expiratory lung volume.
Studies applying NHF immediately after extubation in cardiac surgery patients revealed better oxygenation and less need for advanced methods of respiratory support compared to conventional oxygen devices , and similar results compared to noninvasive ventilation. However, Zochios et al, summarized all the available up to date data of NHF compared to conventional oxygen devices and non-invasive ventilation in patients undergoing cardiothoracic surgery and they did not find any further benefit by NHF use. The aforementioned discrepancy could be explained by the differences in the studied populations and NHF flow settings. The proposed initial flow rate differs among the studies, with some authors suggesting initial lower flows (35-40 L/min) that will be better tolerated by the patients and others suggesting initial maximal flows (60 L/min) to rapidly relieve dyspnea and prevent muscle fatigue.
Aim The primary goal of the study is to evaluate the efficacy of NHF (with initial flows of 60 L/min or 40 L/min) versus conventional oxygen systems on respiratory parameters (respiratory rate, pO2/ FiO2, spO2, use of accessory muscles, dyspnoea, comfort and tolerance by using the visual analogue scale) immediately after the extubation of cardiac surgery patients.
Additional goals of the study are to compare two different initial NHF flows of 60 L/min and 40 L/min, ICU Length of Stay, Hospital Length of Stay, rates of ICU re-admission and re-intubation and any other respiratory / non-respiratory complications and adverse events. Moreover, the rate of failure of the initial treatment will be recorded (as a major measure of treatment efficacy).
Method
This is a prospective, non-blinded, randomized study in post-extubated cardiac surgery patients. The study population will consist of three patient groups:
The first group (Study Group 1) will include patients on NHF with initial settings of FiO2=60% and gas flow=60L/min.
The second group (Study Group 2) will include patients on NHF with initial settings of FiO2=60% and gas flow=40L/min In the third group (control group) all patients will receive oxygen therapy according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min.
Patients in both study groups would be weaned off the NHF as follows; First reducing FiO2 gradually to 50%, and then gradually reducing the gas flow (either from 60l/min or 40/min, depending on the study group) down to 30l/min, aiming at the final wean-off goal of 20l/min, unless the attending physician decides to wean-off patient to Venturi mask directly from a higher gas flow supply (e.g.: 30-25l/min) Treatment failure will be defined as any crossover from one treatment to another due to patient's respiratory distress and discomfort. To be more specific, switch of gas flow from 40L/min to 60L/min, crossover from either NHF group to standard practice (Venturi mask) or need for more advanced respiratory support such as non-invasive ventilation or invasive mechanical ventilation.
Any implemented treatment would also be defined as "failure" when any irreversible (for at least 48 hours) FiO2/gas-mixture flow escalation might be needed, either it is being recorded on Study group 1 & 2 or Control group.
An initial power analysis was based on a predicted, average failure rate of 15% in the 2 NHF groups and a failure rate of 51% in the control group; this analysis yielded the need for enrollment of a total of 41 NHF patients and 21 controls for alpha = 0.05 and power=0.80. To ensure equal numbers of patients in each one of the 2 NHF groups, the authors decided to actually enroll 42 NHF patients (n=21 for each NHF group) and 21 controls, resulting in a total enrollment of 63 patients. At one year after study initiation, actual, total enrollment amounted to 45 patients. At this time point, the Data Monitoring Committee (after confirming the safe application of the study protocol) recommended the continuation of the study until the enrollment of 99 patients (n=33 for each one of the 3 groups); the rationale for this was to compensate for possible dropouts and/or missing data (especially for the secondary and "other" outcomes). Accordingly, the study was completed with an actual enrollment of 99 patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Study Group 1 The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 1, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment. The first Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=60L/min. |
Device: Nasal Cannula High Flow Oxygen
Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
|
| Active Comparator: Study Group 2 The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 2, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment. The second Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=40L/min. |
Device: Nasal Cannula High Flow Oxygen
Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
|
| No Intervention: Control group In the third group (control group) all patients will receive oxygen treatment according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min. In this group all patients will receive the usual standard of care, with no other interventions included |
Outcome Measures
Primary Outcome Measures
- Successful weaning (i.e. absence of treatment failure) from Nasal Cannula High Flow Oxygenation post extubation from cardiac surgery within at least 48 hours [Up to at least 48 hours post extubation or until ICU discharge (predicted cardiothoracic ICU stay could occasionally extend up to 7 days)]
Successful weaning (i.e. absence of treatment failure as further described in methods) would be defined as = 0 when there would be avoided successfully any alternation with other mode of oxygen therapy, or re-intubation, or Non Invasive Ventilation. For all groups: Unsuccessful weaning (i.e. actual treatment failure as further described in methods) would be defined as =1 when there would not be avoided any alternation with other oxygen therapy, re-intubation, Non Invasive Ventilation
Secondary Outcome Measures
- Successful maintenance of Respiration rate within normal range (12-20/min) on initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
Successful maintenance of Respiratory rate within normal range would be defined as = 0. Unsuccessful (=1) if exceeds normal range (12-20/min). Continuous monitoring and recording of implementation of air flow at 60L/min with Nasal Cannula High Flow Oxygenation
- Successful maintenance of Respiration rate within normal range (12-20/min) on initial air flow of 40 L/min with Nasal Cannula High Flow Oxygenation [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
Successful maintenance of Respiratory rate within normal range would be defined as = 0. Unsuccessful (=1) if exceeds normal range (12-20/min). Continuous monitoring and recording of implementation of air flow at 40L/min with Nasal Cannula High Flow Oxygenation
- Successful maintenance of Respiration rate within normal range (12-20/min) with Venturi mask , FiO2: 60%, 15L/min [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
Successful maintenance of Respiratory rate within normal range (12-20/min) would be defined as = 0. Unsuccessful (=1) if exceeds normal range (12-20/min) Continuous monitoring and recording of implementation of Venturi mask FiO2: 60%, 15L/min
- Recording of pO2/FiO2 ratio with initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation [Post extubation period up to 48 hours or ICU discharge]
Continuous monitoring of implementation initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation
- Recording of pO2/FiO2 ratio with initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
Continuous monitoring of implementation initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation
- Recording of pO2/FiO2 ratio with Venturi mask FiO2: 60%, 15L/min [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
Continuous monitoring of implementation Venturi mask, FiO2: 60%, 15L/min
- Successful maintenance of saturation O2 in Hemoglobulin within normal range with initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
Successful maintenace of saturation O2 in Hemoglobulin > 92% would be defined as = 0. If saturation O2 < 92 %, then it would be definded as Unsuccessful = 1 Continuous monitoring and recording of implementation initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation
- Successful maintenance of saturation O2 in Hemoglobulin within normal range with initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
Successful maintenance of saturation O2 in Hemoglobulin within normal range would be defined as = 0. If saturation O2 < 92 %, then it would be definded as Unsuccessful = 1 Continuous monitoring and recording of implementation initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation
- Successful maintenance of saturation O2 in Hemoglobulin within normal range with Venturi mask, FiO2: 60%, 15L/min [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
Successful maintenance of saturation O2 in Hemoglobulin > 92% would be defined as = 0. If saturation O2 < 92 %, then would be defined as Unsuccessful = 1 . Continuous monitoring and recording of implementation Venturi mask FiO2 : 60%, 15L/min.
- Mobilization of accessory respiratory muscles with initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
Success would be defined as = 0 when there would be no mobilization of accessory respiratory muscles. Failure would be defined as = 1 when there would be recorded any mobilization and use of accessory respiratory muscles
- Mobilization of accessory respiratory muscles with initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
Success would be defined as = 0 when there would be no mobilization of accessory respiratory muscles. Failure would be defined as = 1 when there would be recorded any mobilzation and use of accessory respiratory muscles
- Mobilization of accessory respiratory muscles with Venturi mask, FiO2: 60%, 15L/min To record any use of accessory respiratory muscles with Venturi mask , FiO2: 60%, 15L/min [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
Success would be defined as = 0 when there would be no mobilization of accessory respiratory muscles. Failure would be defined as = 1 when there would be recorded any mobilzation and use of accessory respiratory muscles
- Comfort and tolerance of treatment with Visual Analogue Scale with initial air flow at 60 L/min with Nasal Cannula High Flow Oxygenation [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
To monitor and record comfort of patient with the diagnostic tool of Visual Analogue Scale
- Comfort and tolerance of treatment with Visual Analogue Scale with initial air flow at 40 L/min with Nasal Cannula High Flow Oxygenation [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
To monitor and record comfort of patient with the diagnostic tool of Visual Analogue Scale
- Comfort and tolerance of treatment with Visual Analogue Scale with Venturi mask , FiO2: 60%, 15L/min [Post extubation period up to 48 hours or ICU discharge (if cardiothoracic ICU stay was <48 hours)]
To monitor and record comfort of patient with the diagnostic tool of Visual Analogue Scale
Other Outcome Measures
- Length of Stay in the ICU [Post cardiothoracic ICU admission period up to 48 hours or untiI actual cardiothoracic ICU discharge]
There will be recorded the total length of stay in the ICU since admission post surgery
- Length of Stay in the Hospital [Post ICU admission period up to actual hospital discharge]
There will be recorded the total length of stay in the hospital since ICU admission
- Number of participants with death in the cardiothoracic ICU post extubation [Post cardiothoracic ICU admission period up to 48 hours or untiI actual cardiothoracic ICU discharge]
There will be recorded the number of participants that will pass away post extubation in the ICU
- Number of participants with death in the hospital post ICU discharge [Post ICU discharge period up to actual hospital discharge]
There will be recorded the number of participants that will pass away post extubation in the hospital , after the ICU discharge
- Number of participants with Atrial Fibrillation in the ICU post extubation [Post ICU admission period up to 48 hours or actual ICU discharge]
There will be recorded the number of participants that will present Atrial Fibrillation post extubation in the ICU
- Number of participants with any Adverse Events in the ICU [Post cardiothoracic ICU admission period up to 48 hours or untiI actual cardiothoracic ICU discharge]
There will be recorded the number of participants that will present any Adverse Events (respiratory , non-respiratory) post extubation in the ICU
- Number of participants with any Adverse Events in the Hospital [Up to 1 month, or until actual hospital discharge]
There will be recorded the number of participants that will present any Adverse Events (respiratory, non-respiratory) post extubation in the ICU, until hospital discharge.
- Percentage of participants presenting unsuccessful (failed) implementation of NHFO treatment [Post cardiothoracic ICU admission period up to 48 hours or untiI actual cardiothoracic ICU discharge]
There will be recorded the number of participants that will present failure to comply with the treatment due to failing to maintain their respiratory parameters within normal range, or due to presenting intolerance and discomfort to the implementation of NHFO treatment
- Number of participants with re-intubation in the ICU [Post cardiothoracic ICU admission period up to 48 hours or untiI actual cardiothoracic ICU discharge]
There will be recorded the number of participants that will be re-intubated due to deterioration of their respiratory parameters.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Cardiac ICU adult patients
-
18 years
-
After elective or urgent cardiac surgery
-
Successful Spontaneous Breathing Trial (SBT) with T-piece and FiO2=60%.
-
pO2/ FiO2 <200
-
Hemodynamically stable (160>SAP>90mmHg)
Exclusion Criteria:
-
Obstructive Sleep Apnea Syndrome supported by CPAP
-
COPD, officially diagnosed, respiratory failure with serum blood ph <7,35.
-
Patients with tracheostomy,
-
DNR status,
-
Glasgow Coma Scale score < 13,
-
Insufficient knowledge of Greek Language
-
Visual or hearing impairment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Evangelismos General Hospital of Athens | Athens | Attiki | Greece | 10676 |
Sponsors and Collaborators
- National and Kapodistrian University of Athens
Investigators
- Study Chair: Spiros Zakynthinos, Professor, National and Kapodistrian University of Athens
- Study Director: Spiridon Mentzelopoulos, AssProfessor, National and Kapodistrian University of Athens
Study Documents (Full-Text)
More Information
Publications
- NKU Athens